KalVista Pharmaceuticals - developing novel therapies for hereditary angioedema and diabetic macular edema based on small molecule plasma kallikrein inhibitors
KalVista Pharmaceuticals to Present at Stifel Healthcare Conference Wed, 08 Nov 2017 12:30:00 +0000 KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will participate in a fireside chat at the Stifel Healthcare Conference on Wednesday, November 15, 2017, at 8:00 a.m.
KalVista Pharmaceuticals Inc (KALV): Time For A Financial Health Check Sat, 21 Oct 2017 13:56:10 +0000 KalVista Pharmaceuticals Inc (NASDAQ:KALV) is a small-cap stock with a market capitalization of USD $99.96M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies,Read More...
KalVista, Notable Investment and Collaboration Agreement Tue, 17 Oct 2017 12:05:00 +0000 NEW YORK, NY / ACCESSWIRE / October 17, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...
Merck takes stake in small Cambridge rare disease biotech, lifting shares Mon, 16 Oct 2017 17:58:56 +0000 KalVista Pharmaceuticals, a small Cambridge biotech with a pair of rare disease treatments in early-stage studies, saw its market value soar on Tuesday after announcing that drug giant Merck has taken ...
ETFs with exposure to KalVista Pharmaceuticals, Inc. : October 11, 2017 Wed, 11 Oct 2017 15:44:12 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to KalVista Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to KALV-US. Comparing the performance and risk of KalVista Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
(Read more...)
Small-Cap Biotech Rockets After Dow's Merck Buys 10% Stake Tue, 10 Oct 2017 20:06:19 +0000 KalVista shot to a 16-month high Tuesday after it inked a deal with Merck for its eye drugs and allowed the Dow component to take a nearly 10% ownership stake.
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.